Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

This article has no abstract
Epistemonikos ID: 6af708f9c33f093f8bd7c53b39ce36a3713ea016
First added on: Feb 11, 2025